The clinical trial landscape has witnessed a seismic shift in recent years, spurred by technology-driven data collection methods. With an increasing array of data sources available, technology is evolving faster than ever, creating opportunities and challenges. This article – an abstract to our white paper (link) – aims to dispel common myths surrounding data quality in clinical trials and shed light on the evolving data collection, monitoring, and reporting landscape.
Data management and monitoring processes must adapt as data collection methods evolve beyond traditional approaches like electronic case report forms (eCRFs). The challenges posed by this evolution include:
- Diverse Data Sources
Data from multiple sources captured by various systems make aggregation and reconciliation complex and error-prone. - Data Heterogeneity
Not all data holds the same importance, and treating all data equally for review and verification is inefficient. - Scalability
As data volume and velocity increase, traditional data management and monitoring processes become less scalable.
Seeing through the myths and realities of this ever-changing landscape is crucial to adopting modern solutions that enable data quality-driven, risk-based quality management (RBQM).
Myth #1: DCTs are just about capturing data remotely.
Decentralized Clinical Trials (DCTs) go beyond remote data collection; they bring the entire clinical trial ecosystem closer together. Patients benefit from convenience, and sites see improved enrollment and retention. For sponsors and CROs, DCTs automate processes and expedite therapy development.
Myth #2: I need to know much about statistics to make sense of it all.
Access to data analytics should not be restricted to data scientists. Analytics should be accessible to all trial personnel, with outputs presented in user-friendly formats. Simplified analytics allow users to focus on strategic tasks like root cause analysis.
Myth #3: Research misconduct is difficult to identify.
Technology can help identify research misconduct, even when investigators have good intentions. Accurate time/date tracking, tracking precision in reporting vital signs, detecting fraudulent visits, and identifying career patients are examples of how technology can assist in identifying potential misconduct.
Myth #4: Not reducing Source Data Verification (SDV) means not needing RBQM.
Implementing an integrated Risk-Based Quality Management (RBQM) solution involves comprehensive risk management throughout the trial, not just reducing on-site monitoring. Key elements include identifying anticipated risks, reducing risk occurrence probability, mitigating negative impacts, and continuous risk monitoring and closure.
Myth #5: Large amounts of data are needed for RBQM.
Proactive risk management is not limited by study size or data volume. RBQM tools can be tailored to the study's specific needs, even in smaller trials, to identify and mitigate potential risks proactively.
Myth #6: QTLs are just added to satisfy regulators.
Quality Tolerance Limits (QTLs) are essential tools for study management, offering ongoing indicators of systemic study performance issues. They help detect potential issues early and prompt timely actions.
Myth #7: We must accept regional and cultural differences in safety reporting.
Regional and cultural differences in safety reporting are manageable with RBQM tools. Central monitoring teams can analyze site-level and country-level performance to identify and address variations in adverse event reporting.
As the clinical trial landscape evolves, it's essential to dispel common myths about data quality. Identifying research misconduct, implementing RBQM, and monitoring data quality are all possible with the right tools and strategies. By embracing these changes, the clinical trial industry can continue to innovate and improve patient outcomes. Be sure to view our white paper for additional insights.